28-7 Therapeutics raises $65M for cancer drugs aimed at tumor-suppressing RNA

Twentyeight-Seven Therapeutics has launched with $65 million in venture capital to fund its treatments for a variety of cancers, which aim to modulate noncoding strands of microRNA to increase the levels of tumor-suppressing genes.